Achieve Life Sciences, Inc.

Análisis de la acción Achieve Life Sciences, Inc. (QUIT)

$6.060

-0.249 (-4.11%)Al cierre

Loading chart…
Máximo
6.330
Apertura
6.160
Precio medio ponderado por volumen
6.14
Volumen
822.53K
Capitalización
—
Mínimo
6.037
Importe
5.05M
EV/EBITDA, TTM
0.00

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Análisis de IA of Achieve Life Sciences, Inc. (QUIT)

Comprar

BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.

Métricas de valoración

El PER previsto actual de Achieve Life Sciences, Inc. (QUIT) es 0.00, frente a su media de 5 años de .

PER previsto

Media 5A P/E
P/E actual
0.00

EV/EBITDA previsto

Media 5A EV/EBITDA
EV/EBITDA actual
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
20.19
P/S actual
20.19
Sobrevalorada
20.19
Infravalorada
20.19

Ballenas con QUIT en cartera

T

TPG Capital, L.P.

+ Con en carteraQUIT

+27.03%

Rentabilidad a 3 meses

L

Logos Global Management, L.P.

+ Con en carteraQUIT

+24.07%

Rentabilidad a 3 meses

P

Paradigm Biocapital Advisors LP

+ Con en carteraQUIT

+19.24%

Rentabilidad a 3 meses

F

Frazier Life Sciences Management, LP

+ Con en carteraQUIT

+10.54%

Rentabilidad a 3 meses

V

VR Management, LLC

+ Con en carteraQUIT

+9.81%

Rentabilidad a 3 meses

Preguntas frecuentes sobre QUIT, respondidas por Alphio AI

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar